IMTX News & Events

Immatics announced that an abstract highlighting a pediatric patient treated with a PRAME-directed cell therapy using Immatics' PRAME T-cell receptor has been accepted for a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting 2026 in San Diego, California. The patient case will be presented on April 21, at 2:00 pm PDT, by the treating physician, the company stated. Cedrik Britten, M.D., Ph.D., Chief Medical Officer at Immatics, said, "Seeing such a profound response in a pediatric patient who had no treatment options left is both remarkable and deeply encouraging for everyone dedicated to making a meaningful impact on the lives of patients with cancer. It reinforces our belief in PRAME as a powerful target and highlights the potential of cell therapy for pediatric cancers, where tumors often show high PRAME expression. These results support continued evaluation of PRAME-directed cell therapies in pediatric cancers while exploring new therapeutic options for children facing such devastating diseases."

Reports FY25 reports FY25 revenue EUR 48.3M vs. EUR 155.8M last year. "Following a year of strong execution and data updates across our entire PRAME franchise, Immatics is entering 2026 with multiple high-impact milestones ahead, including advancing our PRAME cell therapy, anzu-cel, towards approval," said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. "In parallel, we strive to expand our reach to more patients with our second-generation PRAME cell therapy, IMA203CD8, with meaningful data in gynecologic cancers expected this year, and with our PRAME bispecific IMA402, where we plan to report expanded clinical data supporting initiation of indication-specific expansion cohorts. In addition, we look forward to opening a new therapeutic avenue by initiating a combination study with IMA402 and IMA401, our MAGEA4/8 bispecific, in lung cancer. Above all, we remain focused on translating this positive momentum into transformative outcomes for patients with cancer."